Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncaspar

Sanofi reception

Sanofi buys into AZ drug for preventing RSV infections

Currently there are no approved drugs to treat RSV once established

- PMLiVE

NICE turns down first-line Keytruda for lung cancer

High cost of drug puts it above cost-effectiveness threshold

- PMLiVE

AZ gets US approval for diabetes combo Qtern

Wins licensing for Onglyza/Farxiga dual-therapy after rejection by the FDA in 2015

- PMLiVE

AZ nears EU approval for hyperkalaemia drug Lokelma

CHMP adopts positive opinion for the potassium-binding treatment

- PMLiVE

Riding the wave of digital disruption

The challenges and rewards of meeting consumer expectations

BMS appoints three independent directors

Robert Bertolini, Matthew Emmens and Theodore Samuels join the board

National Institute for Health and Care Excellence NICE logo

Amicus gets NICE green light for Fabry drug

Oral therapy alternative Galafold approved for routine NHS use

AstraZeneca AZ

Generic version of AZ’s Iressa launched in China

Qilu Pharma’s Yiruike licensed as first-line NSCLC treatment

AstraZeneca AZ

AZ agrees to $320m deal for Zoladex

TerSera Therapeutics acquires rights to oncology drug in US and Canada

- PMLiVE

AZ moves closer to Lynparza filing in breast cancer

PARP inhibitor showed “statistically-significant and clinically-meaningful” improvement in phase III trial

- PMLiVE

Gilead Sciences appoints general manager, Canada

Nordics general manager Kennet Brysting moves to take up new post

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links